These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 2769327)

  • 1. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results.
    Wolff SN; Herzig RH; Fay JW; Phillips GL; Lazarus HM; Flexner JM; Stein RS; Greer JP; Cooper B; Herzig GP
    J Clin Oncol; 1989 Sep; 7(9):1260-7. PubMed ID: 2769327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
    Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
    Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
    Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
    Mayer RJ; Davis RB; Schiffer CA; Berg DT; Powell BL; Schulman P; Omura GA; Moore JO; McIntyre OR; Frei E
    N Engl J Med; 1994 Oct; 331(14):896-903. PubMed ID: 8078551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
    Harousseau JL; Milpied N; Briere J; Desablens B; Leprise PY; Ifrah N; Gandhour B; Casassus P
    J Clin Oncol; 1991 Aug; 9(8):1432-7. PubMed ID: 2072146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities.
    Jehn U
    Leuk Lymphoma; 1994 Sep; 15(1-2):99-112. PubMed ID: 7532060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.
    Weick JK; Kopecky KJ; Appelbaum FR; Head DR; Kingsbury LL; Balcerzak SP; Bickers JN; Hynes HE; Welborn JL; Simon SR; Grever M
    Blood; 1996 Oct; 88(8):2841-51. PubMed ID: 8874180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial. Danish Society of Haematology Study Group on AML.
    de Nully Brown P; Hoffmann T; Hansen OP; Boesen AM; Grønbaek K; Hippe E; Jensen MK; Thorling K; Storm HH; Pedersen-Bjergaard J
    Leukemia; 1997 Jan; 11(1):37-41. PubMed ID: 9001416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
    Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
    Bishop JF; Matthews JP; Young GA; Szer J; Gillett A; Joshua D; Bradstock K; Enno A; Wolf MM; Fox R; Cobcroft R; Herrmann R; Van Der Weyden M; Lowenthal RM; Page F; Garson OM; Juneja S
    Blood; 1996 Mar; 87(5):1710-7. PubMed ID: 8634416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cytosine arabinoside and daunorubicin postremission therapy in adults with de novo acute myeloid leukemia. Long-term follow-up of a prospective multicenter trial.
    Heil G; Mitrou PS; Hoelzer D; Freund M; Link H; Ehninger G; Steinke B; Ohl S; Wandt H; Fackler-Schwalbe E
    Ann Hematol; 1995 Nov; 71(5):219-25. PubMed ID: 7492624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
    Damon LE; Rugo HS; Ries CA; Linker CA
    Leukemia; 1994 Apr; 8(4):535-41. PubMed ID: 8152248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R;
    Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Consolidation therapy with high-dose cytarabine and daunorubicin for prolonged disease free survival in acute myelocytic leukemia].
    Qiau Z; Wang C; Yang L
    Zhonghua Nei Ke Za Zhi; 1996 Aug; 35(8):545-8. PubMed ID: 9594148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia.
    Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A
    Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
    Champlin R; Gajewski J; Nimer S; Vollset S; Landaw E; Winston D; Schiller G; Ho W
    J Clin Oncol; 1990 Jul; 8(7):1199-206. PubMed ID: 1694236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults.
    Ohno R; Yokomaku S; Okumura M; Nagai T; Kitaori K; Ito T; Takeo T; Sugiura I; Yano K; Ito Y
    Int J Hematol; 1991 Dec; 54(6):487-93. PubMed ID: 1793832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.